Appointments at Roche, AVI BioPharma, Amgen and Delcath Systems – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Chief financial officer Pharmaceutical companies of the united states

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Roche, AVI BioPharma, Amgen and Delcath Systems.

Roche ​has named Mike Burgess ​as head of oncology discovery and translational area (DTA). Burgess joined Roche in 2006 having previously worked at Eli Lilly.

Robert Bradway ​has been promoted to the position of president and chief operating officer at Amgen​. Bradway has worked at Amgen since 2006 when he joined from Morgan Stanley.

Delcath Systems ​has hired Peter Graham ​to fill the newly created position of executive vice president (EVP) and general counsel. Graham has previously worked at ACIST Medical Systems and E-Z-EM.

David Boyle II​ will work as interim president and CEO of AVI BioPharma​ while continuing in his current position of chief financial officer. Boyle joined AVI from Xoma in 2008.

InteKrin Therapeutics ​has appointed Roman Skowronski ​as VP, clinical development. Skowronski has previously worked at AcelRx, Alza and Alexza.

Joseph Cook ​has been elected to the board of directors at the Tennessee Biotech Association ​(TBA). Before joining TBA Cook held positions at Amylin Pharmaceuticals and Eli Lilly.

BioPhausia AB​has named Niklas Prager​ as chairman of its board of directors. Prager is the current CEO of Qbtech AB and former CEO of Pfizer Sverige.

Michael Polito ​has joined Heritage Pharmaceuticals ​as chief financial officer. Polito was US controller of Barr Pharmaceuticals before the company was acquired by Teva.

Orexigen Therapeutics ​has appointed Wendy Dixon ​to its board of directors. Dixon has previously worked at Bristol-Myers Squibb, Merck & Co and SmithKline French.

William Ringo ​has been named as chairman of the board of directors at Sangamo BioSciences​. Ringo will retire from his post at Pfizer at the end of April. He has also worked at Abgenix, InterMune and Eli Lilly.

Related topics Markets & Regulations

Related news

Show more